- Conditions
- Healthy
- Interventions
- ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 416
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus, Healthy
- Interventions
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cytomegalovirus Infections
- Interventions
- TCN-202, Placebo
- Biological
- Lead sponsor
- Theraclone Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- NTLA-2001, Placebo
- Biological · Drug
- Lead sponsor
- Intellia Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
- Conditions
- Pharmacokinetics of ASKP1240, Healthy Volunteers
- Interventions
- ASP1240, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Emphysema Secondary to Congenital AATD
- Interventions
- OsrhAAT 1 mg/kg IV, OsrhAAT 3 mg/kg IV, OsrhAAT 10 mg/kg IV, OsrhAAT 20 mg/kg IV, OsrhAAT 40 mg/kg IV, OsrhAAT 60 mg/kg IV
- Drug
- Lead sponsor
- Healthgen Biotechnology Corp.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
- Interventions
- Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo
- Radiation · Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Antithymocyte Globulin, Placebo (for ATG)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years to 34 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Orange, California • San Francisco, California • Stanford, California + 17 more
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
- Interventions
- Sodium Nitrite, Normal Saline
- Drug
- Lead sponsor
- Hope Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Fort Worth, Texas
- Conditions
- Heart Disease
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 798 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV Infections
- Interventions
- BMS-936559, Placebo for BMS-936559
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more
- Conditions
- Ischemia-Reperfusion Injury, Lung Transplantation
- Interventions
- Repertaxin, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
- Conditions
- Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
- Interventions
- Phentolamine, Propranolol, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19
- Interventions
- MP0420, Placebo, Remdesivir
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 73
- States / cities
- Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 51
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
- Conditions
- Pain
- Interventions
- Lidocaine, Saline
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- VIB4920, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • Sun City, Arizona • Upland, California + 15 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Efprezimod alfa, Placebo
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin (9-39), Vehicle
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
- Conditions
- COVID-19
- Interventions
- BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
- Conditions
- Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
- Interventions
- BXQ-350, Placebo
- Drug · Other
- Lead sponsor
- Bexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Cardiovascular Disease
- Interventions
- AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
- Biological · Other · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more